Home Tags NASDAQ:HALO

Tag: NASDAQ:HALO

Halozyme Therapeutics Inc. (NASDAQ:HALO) Reports Strong Q3 With Revenue Of $65.3...

Kate Hudson - 0

Halozyme Therapeutics, Inc. (NASDAQ:HALO) And Argenx Expand Their Partnership And License...

Kate Hudson - 0

Halozyme Therapeutics (NASDAQ:HALO) Announce Presentation of Phase 1b Study of Atezolizumab...

Kate Hudson - 0

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Expects To Post Revenues Of $245 Million...

Kate Hudson - 0

Halozyme Therapeutics Inc. (NASDAQ:HALO) Announce That The EMA Has Approved Jannsen’s...

Kate Hudson - 0
© BioPharma Journal 2020
.td-post-views{ display: none !important; }